Vaccines directed to langerhans cells

Abstract

The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.

1 . A vaccine comprising an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the anti-Langerin antibody, wherein when two or more antigens are present, they are separated by one or more linker peptides that comprise at least one glycosylation site. 
     
     
         2 . The vaccine of  claim 1 , wherein the antibody binding fragment is selected from an Fv, Fab, Fab′, F(ab′) 2 , Fc, or a ScFv fragment. 
     
     
         3 . The vaccine of  claim 1 , wherein the antibody comprises one or more complementarity determining regions selected from:
 ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL KISRVEAEDLGLYFCS (SEQ ID NO.: 45);   SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);   VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT ITGAQTEDEAIYFCA (SEQ ID NO.: 47);   SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent thereof.   
     
     
         4 . The vaccine of  claim 1 , wherein the antigenic peptide is a cancer antigen selected from:
 MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ ID NO.: 9);   LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ ID NO.: 10);   LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ ID NO.: 11);   NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ ID NO.: 12);   SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13);   IMDQVPFSV (SEQ ID NO.: 14);   ITDQVPFSV (SEQ ID NO.: 15);   YLEPGPVTV (SEQ ID NO.: 16);   YLEPGPVTA (SEQ ID NO.: 17);   KTWGQYWQV (SEQ ID NO.: 18);   APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR KWIKDTIVANP (SEQ ID NO.: 19);   DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID NO.: 20);   PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA AIPLTSCGSSPVPAS (SEQ ID NO.: 21);   GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO.: 22);   QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL YRYGSFSVTLDIVQ (SEQ ID NO.: 23);   GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);   MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.: 25);   DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);   MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);   QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);   LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ ID NO.: 29); or   AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or binding fragments thereof.   
     
     
         5 . The vaccine of  claim 1 , wherein the antigenic peptide is a viral antigen selected from: 
       
         
           
                 
               
                   (SEQ ID NO.: 31) 
                 
                   VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL; 
                 
                     
                 
                   (SEQ ID NO.: 32) 
                 
                   HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL; 
                 
                     
                 
                   (SEQ ID NO.: 33) 
                 
                   EKIRLRPGGKKKYKLKHIV;  
                 
                     
                 
                 
                 
               
                   (SEQ ID NO.: 34) 
                     
                 
                   NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD; 
                     
                 
                     
                 
                   (SEQ ID NO.: 35) 
                     
                 
                   AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY; 
                     
                 
                     
                 
                   (SEQ ID NO.: 36) 
                     
                 
                   DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIA 
                     
                 
                     
                 
                   PLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFI 
                     
                 
                     
                 
                   DYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGKSSFY 
                     
                 
                     
                 
                   RNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQ 
                     
                 
                     
                 
                   NENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTII 
                     
                 
                     
                 
                   FEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSS 
                     
                 
                     
                 
                   LPYQNIHPVTIGECPKYVRSAKLRMV; 
                     
                 
                     
                 
                   (SEQ ID NO.: 37) 
                     
                 
                   DQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKKHNGKLCDLDGVK 
                     
                 
                     
                 
                   PLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPVNDLCYPGDFN 
                     
                 
                     
                 
                   DYEELKHLLSRINHFEKIQIIPKSSWSSHEASLGVSSACPYQGKSSFF 
                     
                 
                     
                 
                   RNVVWLIKKNSTYPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQTKLYQ 
                     
                 
                     
                 
                   NPTTYISVGTSTLNQRLVPRIATRSKVNGQSGRMEFFWTILKPNDAIN 
                     
                 
                     
                 
                   FESNGNFIAPEYAYKIVKKGDSTIMKSELEYGNCNTKCQTPMGAINSS 
                     
                 
                     
                 
                   MPFHNIHPLTIGECPKYVKSNRLVLA; 
                     
                 
                   or 
                     
                 
                     
                 
                   (SE0 ID NO.: 38) 
                     
                 
                   PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGAT 
                     
                 
                     
                 
                   PQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQM 
                     
                 
                     
                 
                   REPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRM 
                     
                 
                     
                 
                   YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQ 
                     
                 
                     
                 
                   NANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVL. 
                     
                 
             
                
                
                
                
                
                
                
                
                
               
            
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         6 . The vaccine of  claim 1 , wherein the one or more peptide linkers are selected from: 
       
         
           
                 
                 
               
                   SSVSPTTSVHPTPTSVPPTPTKSSP; 
                   (SEQ ID NO.: 39) 
                 
                     
                 
                   PTSTPADSSTITPTATPTATPTIKG; 
                   (SEQ ID NO.: 40) 
                 
                     
                 
                   TVTPTATATPSAIVTTITPTATTKP; 
                   (SEQ ID NO.: 41) 
                 
                   or 
                     
                 
                     
                 
                   TNGSITVAATAPTVTPTVNATPSAA. 
                   (SEQ ID NO.: 42) 
                 
             
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         7 . The vaccine of  claim 1 , wherein the anti-Langerin antibody is selected from the following pairs of amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or binding fragments thereof. 
     
     
         8 . The vaccine of  claim 1 , wherein the anti-Langerin antibody is the expression product of the following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and 77 and 79. 
     
     
         9 . The vaccine of  claim 1 , wherein the anti-Langerin antibody or binding fragment thereof is at least one of 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7 and humanized derivatives thereof. 
     
     
         10 . The vaccine of  claim 1 , wherein the anti-Langerin antibody or binding fragment thereof and the antigenic peptide are a fusion protein. 
     
     
         11 . An isolated nucleic acid vector that expresses an anti-Langerin antibody or binding fragment thereof and two or more antigenic peptides at the carboxy-terminus of the light chain, the heavy chain or both the light and heavy chains of the anti-Langerin antibody, wherein when two or more antigenic peptides are present, the antigenic peptides are separated by the one or more peptide linkers that comprise at least one glycosylation site. 
     
     
         12 . The vector of  claim 11 , wherein the antigenic peptides are cancer peptides selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), β-catenin, MUM-1-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen)1, BAGE (melanoma antigen) 2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance protein (LRP), Bcl-2, and Ki-67. 
     
     
         13 . The vector of  claim 11 , wherein the antigenic peptides are cancer peptides are selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia. 
     
     
         14 . The vector of  claim 11 , wherein the antigenic peptides are selected from Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, Avian Flu (HA5-1), dockerin domain from  C. thermocellum  (doc), HIV gag p24 (gag), or a string of HIV peptides (Lipo5), PSA (KLQCVDLHV)-tetramer, or an HIVgag-derived p24-PLA. 
     
     
         15 . The vector of  claim 11 , wherein the anti-Langerin antibody is selected from the following pairs of amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80 or binding fragments thereof. 
     
     
         16 . The vector of  claim 11 , wherein the anti-Langerin antibody is the expression product of the following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and 77 and 79. 
     
     
         17 . The vector of  claim 11 , wherein the anti-Langerin antibody or binding fragment thereof is at least one of 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7 and humanized derivatives thereof. 
     
     
         18 . The vector of  claim 11 , wherein the anti-Langerin antibody or binding fragment thereof and the antigenic peptide are a fusion protein. 
     
     
         19 . A method of enhancing T and B cell responses comprising:
 immunizing a subject in need of vaccination with an effective amount of a vaccine comprising an isolated fusion protein comprising an anti-Langerin antibody or binding portion thereof and one or more antigenic peptides linked to the carboxy-terminus of the anti-Langerin antibody.   
     
     
         20 . The method of  claim 19 , wherein the antigenic peptides are cancer peptides selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), β-catenin, MUM-1-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen)1, BAGE (melanoma antigen) 2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance protein (LRP), Bcl-2, and Ki-67. 
     
     
         21 . The method of  claim 19 , wherein the antigenic peptides are cancer peptides selected from tumor associated antigens comprising antigens from leukemias, lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia. 
     
     
         22 . The method of  claim 19 , wherein the antigenic peptides are selected from Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain, HLA-A201-FluMP (58-66) peptide (GILGFVFTL) tetramer, Avian Flu (HA5-1), Influenza A Hemagglutinin HA-1 from a H1N1 Flu strain (HA1-1), dockerin domain from  C. thermocellum  (doc), HIV gag p24 (gag), or a string of HIV peptides (Hipo5), PSA (KLQCVDLHV)-tetramer, or an HIVgag-derived p24-PLA. 
     
     
         23 . A method of making an anti-Langerin-antigen fusion protein comprising:
 expressing an isolated fusion protein comprising an anti-Langerin antibody or binding fragment thereof in a host cell, the fusion protein comprising one or more antigenic peptides at the carboxy-terminus of the anti-Langerin antibody or binding fragment thereof, wherein when two or more cancer peptides are present, the cancer peptides are separated by one or more linkers, at least one linker comprising a glycosylation site; and   isolating the fusion protein.   
     
     
         24 . The method of  claim 23 , wherein the fusion protein expressed in the host is further purified. 
     
     
         25 . The method of  claim 23 , wherein the host is a eukaryotic cell. 
     
     
         26 . The method of  claim 23 , wherein the antigenic peptides are cancer peptides selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC-related protein (Mucin) (MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin B1, cyclin D, Pmel 17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), β-catenin, MUM-1-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1 , BAGE (melanoma antigen) 2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance protein (LRP), Bcl-2, and Ki-67. 
     
     
         27 . The method of  claim 23 , wherein the antigenic peptides are cancer peptides selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia. 
     
     
         28 . The method of  claim 23 , wherein the cancer peptides are selected from at least one of:
 MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHP QWV (SEQ ID NO.: 9);   LTAAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSH D (SEQ ID NO.: 10);   LMLLRLSEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVI S (SEQ ID NO.: 11);   NDVCAQVHPQKVTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALP ERP (SEQ ID NO.: 12);   SLYTKVVHYRKWIKDTIVANP (SEQ ID NO.: 13);   IMDQVPFSV (SEQ ID NO.: 14);   ITDQVPFSV (SEQ ID NO.: 15);   YLEPGPVTV (SEQ ID NO.: 16);   YLEPGPVTA (SEQ ID NO.: 17);   KTWGQYWQV (SEQ ID NO.: 18);   APLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLTAAHCIRNKSVILL GRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRLSEPAELTD AVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKV TKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYR KWIKDTIVANP (SEQ ID NO.: 19);   DTTEPATPTTPVTTPTTTKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDCWRG GQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQPVY PQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAML GTHTMEVTVYHRRGSQSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQ (SEQ ID NO.: 20);   PLTFALQLHDPSGYLAEADLSYTWDFGDSSGTLISRAXVVTHTYLEPGPVTAQVVLQA AIPLTSCGSSPVPAS (SEQ ID NO.: 21);   GTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQM PTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAA (SEQ ID NO.: 22);   QVTTTEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVL YRYGSFSVTLDIVQ (SEQ ID NO.: 23);   GIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPACQ LVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIVPGILLTGQEAGLGQ (SEQ ID NO.: 24);   MEMKILRALNFGLGRPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDY (SEQ ID NO.: 25);   DWLVQVQMKFRLLQETMYMTVSIIDRFMQNNCVPKK (SEQ ID NO.: 26);   MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCV (SEQ ID NO.: 27);   QKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATC MFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELL (SEQ ID NO.: 28);   LVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSM V (SEQ ID NO.: 29); or   AAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQA QQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI (SEQ ID NO.: 30), or immunogenic fragments thereof.   
     
     
         29 . A method of expanding antigen-specific T cells or B cells in vitro comprising:
 isolating peripheral blood mononuclear cells (PBMCs) from a cancer patient;   incubating the isolated PBMCs with an immunogenic amount of an isolated anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a tumor associated antigen and x is an integer 1 to 20;   expanding the PBMCs in the presence of an effective amount of IL-2;   harvesting the cells; and   assessing the cytokine production by the cells to determine the presence of anti-cancer specific T cells or B cells.   
     
     
         30 . A tumor associated antigen-specific T cell or B cell made by the method comprising:
 isolating peripheral blood mononuclear cells (PBMCs) from a cancer patient;   incubating the isolated PBMCs with an immunogenic amount of an anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a tumor associated antigen and x is an integer 1 to 20;   expanding the PBMCs in the presence of an effective amount of IL-2;   harvesting the cells; and   assessing the cytokine production by the cells to determine the presence of tumor associated antigen-specific T cells or B cells.   
     
     
         31 . A therapeutic vaccine comprising an isolated fusion protein comprising the formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x; Ab-(Ag-PL-Ag)x; Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an anti-Langerin monoclonal antibody or binding fragment thereof; PL is at least one peptide linker comprising at least one glycosylation site; Ag is at least one infectious disease antigen; and x is an integer from 1 to 20. 
     
     
         32 . A method of expanding antigen-specific T cells or B cells in vitro comprising:
 isolating peripheral blood mononuclear cells (PBMCs) from a patient suspected of having an infection;   incubating the isolated PBMCs with an immunogenic amount of an isolated anti-Langerin-(PL-Ag)x or αLangerin-(Ag-PL)x vaccine, wherein Ag is an antigen of the infectious agent and x is an integer 1 to 20;   expanding the PBMCs in the presence of an effective amount of one or more cytokines;   harvesting the cells; and   assessing the cytokine production by the cells to determine the presence of anti-infections agent specific T cells or B cells.   
     
     
         33 . A viral associated antigen-specific T cell or B cell made by the method comprising:
 isolating peripheral blood mononuclear cells (PBMCs) from a patient suspected of having a viral infection;   incubating the isolated PBMCs with an immunogenic amount of an isolated anti-Langerin-(PL-Ag)x or anti-Langerin-(Ag-PL)x vaccine, wherein Ag is a viral associated antigen and x is an integer 1 to 20;   expanding the PBMCs in the presence of an effective amount of one or more cytokines;   harvesting the cells; and   assessing the cytokine production by the cells to determine the presence of viral associated antigen-specific T cells or B cells.   
     
     
         34 . A therapeutic vaccine comprising an isolated fusion protein comprising the formula: Ab-(PL-Ag)x; Ab-(Ag-PL)x; Ab-(PL-Ag-PL)x; Ab-(Ag-PL-Ag)x; Ab-(PL-Ag)x-PL; or Ab-(Ag-PL)x-Ag; wherein Ab is an anti-Langerin monoclonal antibody or binding fragment thereof; PL is at least one peptide linker comprising at least one glycosylation site; Ag is at least one viral antigen; and x is an integer from 1 to 20. 
     
     
         35 . An isolated antibody comprising one or more of complementarity determining regions selected from:
 ASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTNFTL KISRVEAEDLGLYFCS (SEQ ID NO.: 45);   SVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKGKATLTADK SSTTAYMQLSSLTSEDSAVYFCA (SEQ ID NO.: 46);   VTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRVSGVPARFSGSLIGDKAALT ITGAQTEDEAIYFCA (SEQ ID NO.: 47);   SLKLSCAASGLTFNIYAMNWVRQAPGKGLEWVARIRNKSNNYATYYADSVKDRFTISR DDSQSLLYLQMNNLKTEDTAMYYC (SEQ ID NO.: 48); or a direct equivalent thereof.   
     
     
         36 . The antibody of  claim 27 , wherein the antibody is humanized. 
     
     
         37 . The antibody of  claim 27 , wherein the antibody is 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7, and humanized derivatives thereof. 
     
     
         38 . An isolated nucleic acid that encodes a 15B10, 2G3, 91E7, 37C1, or 4C7 antibody, antibody binding fragment or a humanized derivative thereof. 
     
     
         39 . The nucleic acid of  claim 38 , wherein the anti-Langerin antibody is selected from the following pairs of amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58; and 78 and 80; or binding fragments thereof. 
     
     
         40 . The nucleic acid of  claim 38 , wherein the anti-Langerin antibody is the expression product from the following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and 77 and 79; or binding fragments thereof. 
     
     
         41 . A pharmaceutical composition comprising an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides attached to the anti-Langerin antibody, wherein when two or more antigens are present, they are separated by one or more linker peptides that comprise at least one glycosylation site. 
     
     
         42 . The composition of  claim 41 , wherein the antibody binding fragment is selected from an Fv, Fab, Fab′, F(ab′) 2 , Fc, or a ScFv fragment. 
     
     
         43 . The composition of  claim 41 , wherein the anti-Langerin antibody is selected from the following pairs of amino acid sequences SEQ ID NOS.: 2 and 4; 6 and 7; 52 and 54; 56 and 58;
 and  78  and  80  or binding fragments thereof.   
     
     
         44 . The composition of  claim 41 , wherein the anti-Langerin antibody is the expression product of the following pairs of nucleic acid sequences SEQ ID NOS.: 1 and 3; 5 and 6; 51 and 53; 55 and 57; and 77 and 79. 
     
     
         45 . The composition of  claim 41 , wherein the anti-Langerin antibody or binding fragment thereof is at least one of 15B10 having ATCC Accession No. PTA-9852, 2G3 having ATCC Accession No. PTA-9853, 91E7, 37C1, or 4C7 and humanized derivatives thereof. 
     
     
         46 . The composition of  claim 41 , wherein the anti-Langerin antibody or binding fragment thereof and the antigenic peptide are a fusion protein. 
     
     
         47 . The composition of  claim 41 , wherein the composition further comprises an adjuvant. 
     
     
         48 . The composition of  claim 41 , wherein the composition further comprises one or more pharmaceutical excipients.